Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) Total Equity: ¥8,580 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688336 Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd SHSE:688336
85 GF Score
Price ¥52.31
GF Value ¥67.10
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Sunshine Guojian Pharmaceutical (Shanghai) Co Total Equity?

Sunshine Guojian Pharmaceutical (Shanghai) Co SHSE:688336 +2.75% 85 Total Equity is ¥8,580 Mil as of Mar. 2026. GuruFocus rates SHSE:688336 with a GF Score™ of 85/100 and a GF Value™ of ¥67.10 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Sunshine Guojian Pharmaceutical (Shanghai) Co's total equity for the quarter that ended in Mar. 2026 was ¥8,580 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Sunshine Guojian Pharmaceutical (Shanghai) Co Total Equity Historical Data

* Premium members only.

The historical data trend for Sunshine Guojian Pharmaceutical (Shanghai) Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunshine Guojian Pharmaceutical (Shanghai) Co Total Equity Chart

Sunshine Guojian Pharmaceutical (Shanghai) Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,539.10 4,599.52 4,878.56 5,536.88 8,414.75

Sunshine Guojian Pharmaceutical (Shanghai) Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,637.71 5,663.58 5,858.78 8,414.75 8,580.29
SHSE:688336
85GF Score
Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd SHSE:688336
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sunshine Guojian Pharmaceutical (Shanghai) Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Sunshine Guojian Pharmaceutical (Shanghai) Co's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=8957.374-542.621
=8,415

Sunshine Guojian Pharmaceutical (Shanghai) Co's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=8948.305-368.014
=8,580

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of ¥8,580 Mil mean?
Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) has a Total Equity of ¥8,580 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Sunshine Guojian Pharmaceutical (Shanghai) Co and its competitors.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co's Total Equity too high?
Sunshine Guojian Pharmaceutical (Shanghai) Co's current Total Equity is ¥8,580 Mil. Overall, Sunshine Guojian Pharmaceutical (Shanghai) Co has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sunshine Guojian Pharmaceutical (Shanghai) Co's Total Equity compare to VRTX and REGN?
Sunshine Guojian Pharmaceutical (Shanghai) Co's Total Equity of ¥8,580 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Sunshine Guojian Pharmaceutical (Shanghai) Co and its competitors. Sunshine Guojian Pharmaceutical (Shanghai) Co's current Total Equity is ¥8,580 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co stock overvalued right now?
Based on GuruFocus' analysis, Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥67.10, compared to a current price of ¥52.31 — trading 22% below its estimated fair value. The current Total Equity is ¥8,580 Mil. Sunshine Guojian Pharmaceutical (Shanghai) Co's overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336), the current Total Equity is ¥8,580 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) Overvalued in 2026?

Based on GuruFocus' analysis, Sunshine Guojian Pharmaceutical (Shanghai) Co stock appears to be undervalued. The current stock price of ¥52.31 is trading 22% below its estimated GF Value™ of ¥67.10. GuruFocus considers Sunshine Guojian Pharmaceutical (Shanghai) Co to be Modestly Undervalued.

Key valuation signals for SHSE:688336:

  • Total Equity: ¥8,580 Mil
  • GF Value™: ¥67.10 vs. price of ¥52.31 (22% below fair value)
  • GF Score™: 85/100 with 3 warning signs

No single metric tells the full story. See the SHSE:688336 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sunshine Guojian Pharmaceutical (Shanghai) Co Business Description

Address No.399 Libing Road, China (Shanghai) Pilot Free Trade Zone, Shanghai, CHN, 201203
Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd is a biopharmaceutical company providing safe and effective clinical solutions for the treatment of major diseases such as autoimmune diseases and tumors. The company engages in in research and development, manufacturing and commercialization of therapeutic antibody drugs in China. Its products portfolio includes YISAIPU and Xenopax. Its products in pipeline include 302H, 304R, 602, 601A, 609A and 301S.
85GF Score

Get the complete analysis for SHSE:688336

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥52.31
Price
¥67.10
GF Value